GB9819035D0 - Chemical compounds VII - Google Patents

Chemical compounds VII

Info

Publication number
GB9819035D0
GB9819035D0 GBGB9819035.8A GB9819035A GB9819035D0 GB 9819035 D0 GB9819035 D0 GB 9819035D0 GB 9819035 A GB9819035 A GB 9819035A GB 9819035 D0 GB9819035 D0 GB 9819035D0
Authority
GB
United Kingdom
Prior art keywords
alkyl
disorders
hydrogen
independently selected
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB9819035.8A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ligand UK Research Ltd
Original Assignee
Vernalis Research Ltd
Cerebrus Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vernalis Research Ltd, Cerebrus Ltd filed Critical Vernalis Research Ltd
Priority to GBGB9819035.8A priority Critical patent/GB9819035D0/en
Publication of GB9819035D0 publication Critical patent/GB9819035D0/en
Priority to TR2005/01110T priority patent/TR200501110T2/xx
Priority to BR9913477-2A priority patent/BR9913477A/pt
Priority to CZ20010772A priority patent/CZ296275B6/cs
Priority to PL99346427A priority patent/PL346427A1/xx
Priority to CNB998128341A priority patent/CN1165537C/zh
Priority to ES99943091T priority patent/ES2226430T3/es
Priority to HR20010126A priority patent/HRP20010126B1/xx
Priority to AU56375/99A priority patent/AU758084B2/en
Priority to AT99943091T priority patent/ATE273308T1/de
Priority to DE69919364T priority patent/DE69919364T2/de
Priority to JP2000567532A priority patent/JP2002523508A/ja
Priority to US09/763,889 priority patent/US6433175B1/en
Priority to PT99943091T priority patent/PT1109813E/pt
Priority to EP99943091A priority patent/EP1109813B1/en
Priority to KR1020077011961A priority patent/KR20070062609A/ko
Priority to HK01105681.2A priority patent/HK1034967B/en
Priority to CA002341991A priority patent/CA2341991C/en
Priority to KR1020017002608A priority patent/KR100768595B1/ko
Priority to DK99943091T priority patent/DK1109813T3/da
Priority to IL14165999A priority patent/IL141659A0/xx
Priority to MXPA01002101A priority patent/MXPA01002101A/es
Priority to TR2001/00659T priority patent/TR200100659T2/xx
Priority to HU0103333A priority patent/HUP0103333A3/hu
Priority to SI9930677T priority patent/SI1109813T1/xx
Priority to YU16001A priority patent/YU16001A/sh
Priority to NZ510097A priority patent/NZ510097A/xx
Priority to RU2001108570/04A priority patent/RU2232162C2/ru
Priority to PCT/GB1999/002884 priority patent/WO2000012510A1/en
Priority to IDW20010677A priority patent/ID28842A/id
Priority to ZA200101457A priority patent/ZA200101457B/xx
Priority to IL141659A priority patent/IL141659A/en
Priority to NO20010991A priority patent/NO321527B1/no
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Addiction (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
GBGB9819035.8A 1998-09-01 1998-09-01 Chemical compounds VII Ceased GB9819035D0 (en)

Priority Applications (33)

Application Number Priority Date Filing Date Title
GBGB9819035.8A GB9819035D0 (en) 1998-09-01 1998-09-01 Chemical compounds VII
IDW20010677A ID28842A (id) 1998-09-01 1999-09-01 Piroloindola, piridoindola dan asepinoindola sebagai agonis 5-ht2c
HK01105681.2A HK1034967B (en) 1998-09-01 1999-09-01 Pyrroloindoles, pyridoindoles and azepinoindoles as 5-ht2c agonists
CA002341991A CA2341991C (en) 1998-09-01 1999-09-01 Pyrroloindoles, pyridoindoles and azepinoindoles as 5-ht2c agonists
CZ20010772A CZ296275B6 (cs) 1998-09-01 1999-09-01 Pyrroloindoly, pyridoindoly a azepinoindoly jako agonisté 5-HT2C a jejich pouzití
PL99346427A PL346427A1 (en) 1998-09-01 1999-09-01 Pyrroloindoles, pyridoindoles and azepinoindoles as 5-ht2c agonists
CNB998128341A CN1165537C (zh) 1998-09-01 1999-09-01 作为5-ht2c兴奋剂的吡咯并吲哚、吡啶并吲哚和氮杂�并吲哚
ES99943091T ES2226430T3 (es) 1998-09-01 1999-09-01 Pirroloindoles, piridoindoles y azepinoindoles como agonistas 5-ht2c.
HR20010126A HRP20010126B1 (en) 1998-09-01 1999-09-01 Pyrroloindoles, pyridoindoles and azepinoindoles as 5-ht2c agonists
AU56375/99A AU758084B2 (en) 1998-09-01 1999-09-01 Pyrroloindoles, pyridoindoles and azepinoindoles as 5-HT2C agonists
AT99943091T ATE273308T1 (de) 1998-09-01 1999-09-01 Pyrroloindole, pyridoindole und azepinoindole als 5-ht2c agonisten
DE69919364T DE69919364T2 (de) 1998-09-01 1999-09-01 Pyrroloindole, pyridoindole und azepinoindole als 5-ht2c agonisten
JP2000567532A JP2002523508A (ja) 1998-09-01 1999-09-01 5−ht2cアゴニストとしての、ピロロインドール、ピリドインドールおよびアゼピノインドール
US09/763,889 US6433175B1 (en) 1998-09-01 1999-09-01 Pyrroloindoles, pyridoindoles and azepinoindoles as 5-ht2c agonists
PT99943091T PT1109813E (pt) 1998-09-01 1999-09-01 Pirroloindoles, piridoindoles e azepinoindoles como agonistas de 5-ht2c
EP99943091A EP1109813B1 (en) 1998-09-01 1999-09-01 Pyrroloindoles, pyridoindoles and azepinoindoles as 5-ht2c agonists
KR1020077011961A KR20070062609A (ko) 1998-09-01 1999-09-01 5-ht2c 아고니스트로서의 피롤로인돌, 피리도인돌 및아제피노인돌
TR2005/01110T TR200501110T2 (tr) 1998-09-01 1999-09-01 5-HT2C agonistleri olarak piroloindoller, piridoindoller ve azepinoindoller.
DK99943091T DK1109813T3 (da) 1998-09-01 1999-09-01 Pyrroloindoler, pyridoindoler og azepinoindoler som 5-HT2C-agonister
BR9913477-2A BR9913477A (pt) 1998-09-01 1999-09-01 Composto quìmico, utilização e método de fabricação do composto quìmico, composição farmacêutica e método de tratamento de disfunções
KR1020017002608A KR100768595B1 (ko) 1998-09-01 1999-09-01 5-ht2c 아고니스트로서의 피롤로인돌, 피리도인돌 및아제피노인돌
IL14165999A IL141659A0 (en) 1998-09-01 1999-09-01 Pyrroloindoles, pyridoindoles and azepinoindoles as 5-ht2c agonists
MXPA01002101A MXPA01002101A (es) 1998-09-01 1999-09-01 Pirroloindoles, piridoindoles y azepinoindoles como agonistas del receptor 5-ht2c.
TR2001/00659T TR200100659T2 (tr) 1998-09-01 1999-09-01 5-HT2C agonistleri olarak piroloindoller, piridoindoller ve azepinoindoller.
HU0103333A HUP0103333A3 (en) 1998-09-01 1999-09-01 Pyrroloindoles, pyridoindoles and azepinoindiles as 5-ht2c agonists, process for their preparation and pharmaceutical compositions containing them
SI9930677T SI1109813T1 (en) 1998-09-01 1999-09-01 Pyrroloindoles, pyridoindoles and azepinoindoles as 5-ht2c agonists
YU16001A YU16001A (sh) 1998-09-01 1999-09-01 Piroloindoli, piridoindoli i azepinoindoli kao 5-ht2c agonisti
NZ510097A NZ510097A (en) 1998-09-01 1999-09-01 Pyrroloindoles, pyridoindoles and azepinoindoles useful as 5-HT2C agonists
RU2001108570/04A RU2232162C2 (ru) 1998-09-01 1999-09-01 Пирролоиндолы, пиридиноиндолы и азепиноиндолы в качестве агонистов 5-нт2с
PCT/GB1999/002884 WO2000012510A1 (en) 1998-09-01 1999-09-01 Pyrroloindoles, pyridoindoles and azepinoindoles as 5-ht2c agonists
ZA200101457A ZA200101457B (en) 1998-09-01 2001-02-21 Pyrroloindoles, pyridoindoles and azepinoindoles as 5-HT2C agonists.
IL141659A IL141659A (en) 1998-09-01 2001-02-26 Pyroloindoles, pyridoindoles and azpinoindoles bearing the 2-aminoalkyl group as HT2c-5 agonists and pharmaceutical preparations containing them
NO20010991A NO321527B1 (no) 1998-09-01 2001-02-27 Pyrroloindoler, pyridoindoler og azepinoindol-derivater, anvendelse av disse ved fremstilling av et medikament, farmasoytisk preparat omfattende slike og fremgangsmate for fremstilling av preparatet.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9819035.8A GB9819035D0 (en) 1998-09-01 1998-09-01 Chemical compounds VII

Publications (1)

Publication Number Publication Date
GB9819035D0 true GB9819035D0 (en) 1998-10-28

Family

ID=10838167

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB9819035.8A Ceased GB9819035D0 (en) 1998-09-01 1998-09-01 Chemical compounds VII

Country Status (29)

Country Link
US (1) US6433175B1 (enExample)
EP (1) EP1109813B1 (enExample)
JP (1) JP2002523508A (enExample)
KR (2) KR20070062609A (enExample)
CN (1) CN1165537C (enExample)
AT (1) ATE273308T1 (enExample)
AU (1) AU758084B2 (enExample)
BR (1) BR9913477A (enExample)
CA (1) CA2341991C (enExample)
CZ (1) CZ296275B6 (enExample)
DE (1) DE69919364T2 (enExample)
DK (1) DK1109813T3 (enExample)
ES (1) ES2226430T3 (enExample)
GB (1) GB9819035D0 (enExample)
HR (1) HRP20010126B1 (enExample)
HU (1) HUP0103333A3 (enExample)
ID (1) ID28842A (enExample)
IL (2) IL141659A0 (enExample)
MX (1) MXPA01002101A (enExample)
NO (1) NO321527B1 (enExample)
NZ (1) NZ510097A (enExample)
PL (1) PL346427A1 (enExample)
PT (1) PT1109813E (enExample)
RU (1) RU2232162C2 (enExample)
SI (1) SI1109813T1 (enExample)
TR (2) TR200501110T2 (enExample)
WO (1) WO2000012510A1 (enExample)
YU (1) YU16001A (enExample)
ZA (1) ZA200101457B (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6960579B1 (en) 1998-05-19 2005-11-01 Alcon Manufacturing, Ltd. Serotonergic 5HT7 receptor compounds for treating ocular and CNS disorders
GB9902047D0 (en) * 1999-01-29 1999-03-17 Cerebrus Ltd Chemical compounds XI
US6465467B1 (en) 1999-05-21 2002-10-15 Biovitrum Ab Certain aryl-aliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases
GB9918965D0 (en) * 1999-08-11 1999-10-13 Cerebrus Ltd Chemical compounds xxi
SE0002754D0 (sv) * 2000-07-21 2000-07-21 Pharmacia & Upjohn Ab New pharmaceutical combination formulation and method of treatment with the combination
US6818639B2 (en) 2000-07-21 2004-11-16 Biovitrum Ab Pharmaceutical combination formulation and method of treatment with the combination
JP4204315B2 (ja) 2000-11-20 2009-01-07 ビオヴィトルム・アクチボラゲット(プブリクト) セロトニン5−ht2レセプターのアンタゴニストとしてのピペラジニルピラジン化合物
SE0004245D0 (sv) 2000-11-20 2000-11-20 Pharmacia Ab Novel compounds and their use
HUP0303316A2 (hu) 2000-12-20 2004-01-28 Bristol-Myers Squibb Pharma Company Aril- és amino-aril-szubsztituált szerotoninreceptor agonista és antagonista ligandumok és ezeket tartalmazó gyógyszerkészítmények
BR0116605A (pt) * 2000-12-27 2003-09-30 Hoffmann La Roche Composto, processo para a preparação de um composto, composição farmacêutica que compreende o mesmo, sua utilização e processo para o tratamento e profilaxia de distúrbios do sistema nervoso central, distúrbios cardiovasculares, distúrbios gastrintestinais e apnéia do sono
AU2002259312B2 (en) 2001-06-01 2007-01-04 Alcon, Inc. Novel arylaminopropane analogues and their use for the treatment of glaucoma
CA2447156A1 (en) 2001-06-01 2002-12-12 Alcon, Inc. Novel fused indazoles and indoles and their use for the treatment of glaucoma
ATE318821T1 (de) 2001-06-01 2006-03-15 Alcon Inc Pyranoindazole und ihre verwendung in der glaukombehandlung
TW593302B (en) 2001-12-20 2004-06-21 Alcon Inc Novel benzodifuranimidazoline and benzofuranimidazoline derivatives and their use for the treatment of glaucoma
BR0311970A (pt) 2002-06-19 2005-03-29 Biovitrum Ab Novos compostos, seu uso e preparação
JP2006501245A (ja) * 2002-08-30 2006-01-12 アルコン,インコーポレイテッド 置換された5−クロマン−5−イル−エチルアミン化合物および緑内障の治療のためのその使用
BR0316775A (pt) 2002-12-13 2005-11-01 Alcon Inc Novos análogos de benzopirano e seu uso para o tratamento de glaucoma
CL2004000826A1 (es) 2003-04-25 2005-03-04 Pfizer Uso de un agonista para el receptor 5-ht2c para preparar un medicamento util en el tratamiento de la incontinencia urinaria provocada por estres, con la condicion de que el agonista no sea 1-[6-cloro-5-(trifluorometil)-2-piridinil]piperazina (org-129
GB0314967D0 (en) * 2003-06-26 2003-07-30 Hoffmann La Roche Piperazine derivatives
US7435837B2 (en) * 2003-10-24 2008-10-14 Wyeth Dihydrobenzofuranyl alkanamine derivatives and methods for using same
US7476687B2 (en) 2003-11-26 2009-01-13 Alcon, Inc. Substituted furo[2,3-g]indazoles for the treatment of glaucoma
US7338972B1 (en) 2003-12-15 2008-03-04 Alcon, Inc. Substituted 1-alkylamino-1H-indazoles for the treatment of glaucoma
AR046890A1 (es) 2003-12-15 2005-12-28 Alcon Inc [1,4] oxazino [2,3-g] indazoles sustituidos para el tratamiento del glaucoma.
US7129257B1 (en) 2003-12-15 2006-10-31 Alcon, Inc. Pyrazolo[3,4- e]benzoxazoles for the treatment of glaucoma
JP5173190B2 (ja) 2004-08-25 2013-03-27 武田薬品工業株式会社 腹圧性尿失禁の予防・治療剤及びそのスクリーニング方法
BRPI0517955A (pt) 2004-11-01 2008-10-21 Wyeth Corp indolizinas substituìdas e derivados como agentes de snc
WO2006062839A1 (en) 2004-12-08 2006-06-15 Alcon, Inc. Use of dioxindoindazoles and dioxoloindazoles for treating glaucoma
NZ560917A (en) 2005-03-31 2011-01-28 Pfizer Prod Inc Cyclopentapyridine and tetrahydroquinoline derivatives
FR2884252B1 (fr) * 2005-04-08 2007-05-18 Aventis Pharma Sa Nouveaux derives d'isoindoles, compositions les contenant, leur preparation et leurs utilisations pharmaceutiques notamment en tant qu'inhibiteurs d'activites de la proteine chaperone hsp90
EP1879875A1 (en) * 2005-04-22 2008-01-23 Wyeth Crystal forms opf {[(2r)-7-(2,6-dichlorophenyl)-5-fluoro-2,3-dihydro-1-benzofuran-2-yl]methyl}amine hydrochloride
CA2609634C (en) * 2005-05-03 2011-02-01 F. Hoffmann-La Roche Ag Tetracyclic azapyrazinoindolines as 5-ht2 ligands
JP5528699B2 (ja) 2006-05-16 2014-06-25 武田薬品工業株式会社 縮合複素環化合物およびその用途
ATE496894T1 (de) * 2006-07-14 2011-02-15 Pfizer Prod Inc Tartratsalz von (7s)-7-ä(5-fluor-2-
JP5520051B2 (ja) 2007-11-15 2014-06-11 武田薬品工業株式会社 縮合ピリジン誘導体およびその用途
KR101062376B1 (ko) 2008-04-10 2011-09-06 한국화학연구원 신규 인돌 카르복실산 비스피리딜 카르복사마이드 유도체,이의 제조방법 및 이를 유효성분으로 함유하는 조성물
WO2011071136A1 (ja) 2009-12-11 2011-06-16 アステラス製薬株式会社 線維筋痛症治療剤
US20130267500A1 (en) 2010-09-01 2013-10-10 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists in the treatment of disorders ameliorated by reduction of norepinephrine level
CN102964352B (zh) * 2012-11-23 2015-04-08 华中师范大学 具有生物活性的手性2,3-二氢吡咯[1,2-a]吲哚衍生物及其不对称合成方法
WO2015066344A1 (en) 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use
WO2019131902A1 (ja) 2017-12-27 2019-07-04 武田薬品工業株式会社 腹圧性尿失禁および便失禁の治療薬
WO2020072675A1 (en) 2018-10-02 2020-04-09 Northwestern University Beta-carbolines as positive allosteric modulators of the human serotonin receptor 2c (5-ht2c)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3250783A (en) * 1964-09-21 1966-05-10 American Cyanamid Co Novel pyrrolo (1, 2-alpha) indoles
US4134894A (en) * 1978-05-04 1979-01-16 Warner-Lambert Company Pyrrolo[1,2-a]indole compounds
GB8416724D0 (en) * 1984-06-30 1984-08-01 Sorbio Sa Lab Active compounds
US4778812A (en) * 1987-06-12 1988-10-18 American Home Products Corporation 2,3-dihydro-9-methyl-1H-pyrrolo[1,2-a]indol-1-amines and derivatives thereof
GB8802127D0 (en) * 1988-02-01 1988-03-02 Glaxo Group Ltd Chemical compounds
MC2096A1 (fr) * 1989-02-23 1991-02-15 Hoffmann La Roche Pyrroles substitues
RU2104279C1 (ru) * 1992-03-12 1998-02-10 Смитклайн Бичам Плс Конденсированное индольное производное или его фармацевтически приемлемая соль, фармацевтическая композиция, проявляющая активность антагониста 5-нт*004-рецептора
EP0572863A1 (de) * 1992-06-05 1993-12-08 F. Hoffmann-La Roche Ag ZNS Pyrazinoindole
TW251284B (enExample) * 1992-11-02 1995-07-11 Pfizer
EP0688216A1 (en) * 1993-03-08 1995-12-27 Fujisawa Pharmaceutical Co., Ltd. Medicament for treating or preventing cerebrovascular diseases
US5629427A (en) * 1993-08-26 1997-05-13 Peterson; Dwight M. 2,7-diaminomitosene analogues

Also Published As

Publication number Publication date
PL346427A1 (en) 2002-02-11
HK1034967A1 (en) 2001-11-09
HRP20010126A2 (en) 2002-02-28
WO2000012510A1 (en) 2000-03-09
KR100768595B1 (ko) 2007-10-18
JP2002523508A (ja) 2002-07-30
MXPA01002101A (es) 2002-08-20
ID28842A (id) 2001-07-05
CZ2001772A3 (cs) 2001-07-11
US6433175B1 (en) 2002-08-13
EP1109813B1 (en) 2004-08-11
TR200100659T2 (tr) 2001-10-22
AU758084B2 (en) 2003-03-13
CN1325399A (zh) 2001-12-05
HUP0103333A2 (hu) 2002-01-28
DE69919364T2 (de) 2005-08-04
ZA200101457B (en) 2002-02-21
ES2226430T3 (es) 2005-03-16
NO321527B1 (no) 2006-05-15
HRP20010126B1 (en) 2005-06-30
DK1109813T3 (da) 2004-12-20
CN1165537C (zh) 2004-09-08
YU16001A (sh) 2003-10-31
EP1109813A1 (en) 2001-06-27
HUP0103333A3 (en) 2002-07-29
IL141659A (en) 2007-10-31
NO20010991L (no) 2001-04-23
CZ296275B6 (cs) 2006-02-15
RU2232162C2 (ru) 2004-07-10
IL141659A0 (en) 2002-03-10
KR20010079715A (ko) 2001-08-22
SI1109813T1 (en) 2005-02-28
NO20010991D0 (no) 2001-02-27
CA2341991A1 (en) 2000-03-09
DE69919364D1 (de) 2004-09-16
NZ510097A (en) 2003-06-30
KR20070062609A (ko) 2007-06-15
AU5637599A (en) 2000-03-21
TR200501110T2 (tr) 2005-07-21
BR9913477A (pt) 2001-10-09
ATE273308T1 (de) 2004-08-15
CA2341991C (en) 2009-04-07
PT1109813E (pt) 2004-11-30

Similar Documents

Publication Publication Date Title
IL141659A0 (en) Pyrroloindoles, pyridoindoles and azepinoindoles as 5-ht2c agonists
GB9819019D0 (en) Chemical compounds II
GB9819032D0 (en) Chemical compounds IV
WO2000017170A3 (en) N1-substituted benzopyrazoles as inhibitors of 5-ht2 receptors
WO2000012482A3 (en) Indazole derivatives with 5-ht2 receptor activity
HUP0301201A2 (hu) Kinazolinonok és kinazolinonokat tartalmazó készítmények
BG106526A (en) Therapeutic quinazoline derivatives
GR3030643T3 (en) Heteroaromatic oxazole compounds and use thereof
AR029815A1 (es) Derivados aza-indolicos, un proceso para su preparacion, composicion farmaceutica, un metodo para su elaboracion y el uso de dichos derivados para la manufactura de un medicamento
MY119623A (en) Quinoline and quinazoline compounds useful in therapy, particularly in the treatment of benign prostatic hyperplasia
GB0018272D0 (en) Chemical compounds IV
WO2001012602A8 (en) Condensed indoline derivatives and their use as 5ht, in particular 5ht2c, receptor ligands
TW239140B (enExample)
NZ336754A (en) Aminobenzophenones as inhibitors of interleukin and TNF
TW200508221A (en) New azetidine compounds
GB9916374D0 (en) Chemical compounds
DK1049672T3 (da) Azetidincarboxamid-derivater til behandling af CNS-lidelser
DK1049670T3 (da) Azetidincarboxamidderivater til behandling af CNS-lidelser
PT1068199E (pt) N-ariloxietil-indoli-alquilaminas para o tratamento da depressao

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)